Karl Naegler
Karl joined Ventech in 2009 and is a General Partner in the Life Sciences sector, as well as Director on the Boards of ActoGenix and Covagen.
Having previously worked with Atlas Venture (London and Munich) for close to eight years, he was instrumental for the formation and financing of several start ups across Europe.
Karl worked closely with U3 Pharma prior to its acquisition by Daiichi Sankyo in 2008 and served on the boards of Nitec Pharma and Lumavita.
Karl has a PhD in molecular neurobiology and MSc in Biology.